Format

Send to

Choose Destination
J Nucl Med. 2017 Sep;58(Suppl 2):91S-96S. doi: 10.2967/jnumed.116.186825.

Therapeutic Radiometals Beyond 177Lu and 90Y: Production and Application of Promising α-Particle, β--Particle, and Auger Electron Emitters.

Author information

1
Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institut, Villigen-PSA, Switzerland.
2
Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland; and.
3
Laboratory of Radiochemistry, Paul Scherrer Institut, Villigen-PSA, Switzerland.
4
Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institut, Villigen-PSA, Switzerland roger.schibli@psi.ch.

Abstract

In recent years, new α-particle-, β--particle-, and Auger electron-emitting radiometals-such as 67Cu, 47Sc, 166Ho, 161Tb, 149Tb, 212Pb/212Bi, 225Ac, and 213Bi-have been produced and evaluated (pre)clinically for therapeutic purposes. In this short review article, the most important routes of production of these radiometals are critically discussed, as are examples of their application in preclinical and clinical studies.

KEYWORDS:

Auger electrons; radiometals; radionuclide therapy; α-particles; β−-particles

PMID:
28864619
DOI:
10.2967/jnumed.116.186825
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center